Pneumococcal vaccine conjugate 7-valent - Pfizer

Drug Profile

Pneumococcal vaccine conjugate 7-valent - Pfizer

Alternative Names: 7vPNC; PCV7; PNCRM5; PNCRM7; Pneumococcal 7-valent CRM197 vaccine conjugate; Prevenar; Prevnar

Latest Information Update: 18 Mar 2015

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media; Pneumococcal infections; Pneumonia

Most Recent Events

  • 20 Apr 2011 Registered for Pneumococcal infections in China (IM)
  • 26 Nov 2009 Wyeth initiates a phase II trial in children and adolescents in the US (NCT00824850)
  • 16 Oct 2009 Registered for Pneumococcal infections in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top